Commentary
This review by SL Attia et al. (University of Kentucky College of Medicine, USA) summarises emerging pharmacotherapies for the treatment of adult and paediatric NAFLD.
Investigated pharmacotherapies include lanifibranor (IVA337), an indole sulfonamide PPAR agonist that activates all three PPAR subtypes, giving it the potential to address all the key features of NASH, namely inflammation, steatosis, ballooning and fibrosis.
Hepatic inflammatory responses in liver fibrosis